EUVIMEDOpdag EUVIMED
Crossref

High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma

Hirokazu Kobushi, Satoshi Saida iD, Katsutsugu Umeda iD, Atsushi Iwai, Kagehiro Kozuki, Hirohito Kubota iD, Kuniaki Tanaka, Satoshi Obu, Yoshinori Uchihara, Keiji Tasaka iD, Itaru Kato iD, Hidefumi Hiramatsu and 1 more

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30331 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Hirokazu Kobushi and 12 co-authors. Institution: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Major MEDLINE topics: Neuroblastoma. Cited 4 times so far (Crossref); 18 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

There is no clear consensus on the most effective treatment for relapsed/refractory high‐risk neuroblastoma (NB). We retrospectively assessed seven NB patients with relapsed/refractory disease who received high‐dose carboplatin–irinotecan–temozolomide (HD‐CIT). Five of seven patients showed favorable therapeutic response (complete remission or partial remission). Regarding toxicity, the cytopenia period tended to prolong when more than three cycles were repeated, but nonhematological toxicities were controllable with general supportive care. Due to its antitumor efficacy and well‐tolerated nonhematologic toxicity, HD‐CIT is a promising salvage chemotherapy for relapsed/refractory NB. However, it is important to pay attention to the exacerbation of hematological toxicity when repeating the regimen.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaHumansCarboplatinIrinotecanTemozolomideRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyNeoplasm Recurrence, Local

Author keywords

HD-CIThigh-risk neuroblastomairinotecanrefractoryrelapsedsalvage chemotherapytemozolomide

Substances

CarboplatinIrinotecanTemozolomide

Authors and institutions

  • Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID profiles: Satoshi Saida, Katsutsugu Umeda, Hirohito Kubota, Keiji Tasaka, Itaru Kato

Cite

APA

Kobushi, H., Saida, S., Umeda, K., Iwai, A., Kozuki, K., Kubota, H., Tanaka, K., Obu, S., Uchihara, Y., Tasaka, K., Kato, I., Hiramatsu, H., & Takita, J. (2023). High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30331

Vancouver

Kobushi H, Saida S, Umeda K, Iwai A, Kozuki K, Kubota H, et al. High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30331

BibTeX
@article{Kobushi2023,
  author = {Kobushi, Hirokazu and Saida, Satoshi and Umeda, Katsutsugu and Iwai, Atsushi and Kozuki, Kagehiro and Kubota, Hirohito and Tanaka, Kuniaki and Obu, Satoshi and Uchihara, Yoshinori and Tasaka, Keiji and Kato, Itaru and Hiramatsu, Hidefumi and Takita, Junko},
  title = {High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30331}
}
Start for free →